AHRQ on gauging macular degeneration
This article was originally published in The Gray Sheet
Executive Summary
Agency for Healthcare Research & Quality posts final 1technology assessment on the scientific validity of patient-reported outcomes for age-related macular degeneration, identifying vision-specific questionnaires such as NEI-VFQ and VF-14 as the most appropriate quality-of-life instruments that still correspond "moderately" with traditional visual performance measures. CMS' Medicare Coverage Advisory Committee has considered such issues when weighing available evidence supporting AMD treatments (2"The Gray Sheet" Nov. 28, 2005, p. 7)...
You may also be interested in...
MCAC To Weigh Emerging Treatments For Age-Related Macular Degeneration
CMS' Medicare Coverage Advisory Committee will convene Nov. 29 in Baltimore to evaluate the evidence for age-related macular degeneration (AMD) treatments
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.